Search

Editors

Richard L. Cassin Publisher and Editor

Andy Spalding Senior Editor

Jessica Tillipman Senior Editor

Elizabeth K. Spahn Editor Emeritus

Cody Worthington Contributing Editor

Julie DiMauro Contributing Editor

Thomas Fox Contributing Editor

Marc Alain Bohn Contributing Editor

Bill Waite Contributing Editor

Shruti J. Shah Contributing Editor

Russell A. Stamets Contributing Editor

Richard Bistrong Contributing Editor 

Eric Carlson Contributing Editor

Bill Steinman Contributing Editor

Aarti Maharaj Contributing Editor


Connect
FCPA Blog Daily News

Entries in AstraZeneca (11)

Thursday
Apr202017

Elizabeth David-Barrett: Pharmas and the repeated failure of anti-bribery compliance

Pharmaceuticals companies continue to fall foul of the FCPA and other anti-bribery laws, with a number of 2016 cases suggesting a vulnerability around marketing practices especially in the Asia-Pacific region. Why does a sector that is way ahead of the compliance game in so many ways keep getting caught out by anti-bribery laws?

Click to read more ...

Wednesday
Jan042017

Compliance Alert: Speaker fees are often toxic

Last month Forest Labs paid $38 million to settle allegations it paid doctors speaker fees for sometimes phony events so they would prescribe its drugs. It was the latest in a string of "speaker fee" cases.

Click to read more ...

Wednesday
Aug312016

AstraZeneca pays $5.5 million to resolve China, Russia FCPA offenses

The Securities and Exchange Commission Tuesday charged U.K.-based pharma AstraZeneca PLC with violating the books and records and internal controls provisions of the Foreign Corrupt Practices Act when wholly-owned subsidiaries in China and Russia made illegal payments to boost drug sales.

Click to read more ...

Friday
Feb202015

Two AstraZeneca whistleblowers share $1.4 million in FCA settlement

Pharma AstraZeneca LP agreed to pay $7.9 million to settle allegations that it violated the False Claims Act by paying kickbacks to sell its drugs, the DOJ said Wednesday.

Click to read more ...

Wednesday
Sep042013

Bribery part of GSK business plan, China police say

Image courtesy of GlaxoSmithKlineA police investigation in China has found that drugmaker GlaxoSmithKline's alleged bribery of doctors ‘was coordinated by the British company and was not the work of individual employees,’ according to a report Tuesday by Reuters.

Click to read more ...

Monday
Aug262013

Drug sellers ‘take vacations’ amid China anti-graft campaign 

Pharmas have told their sales teams to halt all activity in China to avoid being caught in the nationwide “enforcement storm,” according to the Guangdong-based Yangcheng Evening News.

Click to read more ...

Sunday
Aug112013

Sanofi hit with China bribe probe

China state media reported Saturday that French drugmaker Sanofi SA is under investigation for allegedly bribing doctors to increase sales.

Click to read more ...

Wednesday
Aug072013

Quick look at Big Pharma’s U.S. rap sheet

Recent turbulence in China for drug makers follows big problems for members of the industry in the United States, where they've paid billions in criminal fines and civil penalties.

Click to read more ...

Wednesday
Jul242013

Pharma's China crack up

The headlines from Tuesday's ethiXbase Monitor, a daily email of global corruption and compliance news, tell the story.

Click to read more ...

Thursday
Mar142013

Docs collect billions for drug promos

ProPublica ran an exposé this week about big bucks for doctors who promote products for drug companies.

Click to read more ...

Tuesday
Nov082011

AZ Indicted For Bribery In Serbia

U.K.-based pharma AstraZeneca said its office in Belgrade, Serbia was served with a criminal indictment 'relating to allegations that local employees . . . made allegedly improper payments to physicians at the Institute of Oncology and Radiology of Serbia.'

Click to read more ...